Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | PAK1 | Q13153 | 9/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.49 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.43 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.43 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018418 | 0.90 | CYP1A2 (0.46) | CYP1A2CYP2D6PAK1MCHR1SUV39H1 | |
| SCHEMBL4018965 | 0.87 | CYP1A2 (0.54) | CYP1A2CYP2D6PAK1SUV39H1PRMT1 | |
| SCHEMBL4024856 | 0.85 | PAK1 (0.67) | CYP1A2CYP2D6PAK1SUV39H1PRMT1 | |
| SCHEMBL4018931 | 0.85 | ALDH1A1 (0.60) | MCHR1 | |
| SCHEMBL4584564 | 0.84 | MCHR1 (0.51) | CYP1A2PAK1MCHR1CRHR1 | |
| SCHEMBL4022769 | 0.84 | CYP1A2 (0.55) | CYP1A2CYP2D6PAK1SUV39H1PRMT1 | |
| SCHEMBL4024034 | 0.83 | PAK1 (0.55) | CYP1A2CYP2D6PAK1SUV39H1PRMT1 | |
| SCHEMBL4017800 | 0.83 | PAK1 (0.55) | CYP1A2CYP2D6PAK1SUV39H1PRMT1 | |
| SCHEMBL4024568 | 0.83 | PAK1 (0.68) | CYP1A2CYP2D6PAK1SUV39H1PRMT1 | |
| SCHEMBL4019280 | 0.83 | CYP1A2 (0.54) | CYP1A2CYP2D6PAK1SUV39H1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066654-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | Bayer Schering Pharma AG (DE) | 2009-06-10 | — | — | EP | claimed |
| EP-1903038-A1 | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2008028691-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | claimed |
| EP-1903038-A1 | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |